Last reviewed · How we verify

BPN14770/ zatolmilast — Competitive Intelligence Brief

BPN14770/ zatolmilast (BPN14770/ zatolmilast) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Phosphodiesterase 4D (PDE4D) inhibitor. Area: Neurology.

phase 3 Phosphodiesterase 4D (PDE4D) inhibitor PDE4D Neurology Small molecule Live · refreshed every 30 min

Target snapshot

BPN14770/ zatolmilast (BPN14770/ zatolmilast) — Tetra Discovery Partners. BPN14770 is a phosphodiesterase 4D (PDE4D) inhibitor that increases intracellular cAMP levels to enhance cognitive function and reduce neuroinflammation.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
BPN14770/ zatolmilast TARGET BPN14770/ zatolmilast Tetra Discovery Partners phase 3 Phosphodiesterase 4D (PDE4D) inhibitor PDE4D

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Phosphodiesterase 4D (PDE4D) inhibitor class)

  1. Tetra Discovery Partners · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). BPN14770/ zatolmilast — Competitive Intelligence Brief. https://druglandscape.com/ci/bpn14770-zatolmilast. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: